Aarhus, Denmark – 9 May 2024 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today exits from stealth with €16m in seed ...

Journal in the field and provides all-inclusive access to the critical pillars of human gene therapy: research, methods, and clinical applications. Recent clinical trials utilizing high doses of adeno ...

Researchers at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have discovered a new class of proteins that protect synapses from being destroyed. Synapses are the ...

Financing led by Bioqube Ventures and Novo Holdings Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Its unique ...

Commit is a spin-out from Aarhus University in Denmark, which has built a global reputation as a center of excellence in complement system biology over the last three decades. The Company was ...